Neurofeedback for Obsessive-Compulsive Disorder (OCD)



Status:Recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:2/8/2018
Start Date:July 2015
End Date:July 2019
Contact:Mariela Rance
Email:ocdnfresearch@yale.edu
Phone:203-737-6055

Use our guide to learn which trials are right for you!

Neurofeedback of Activity in the Orbitofrontal Cortex for OCD

The aim of this study is to train patients with obsessive-compulsive disorder to control a
region of their brain that has been associated with their symptoms. Patients in the
experimental group will be given direct feedback regarding activity in this brain area while
they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to
learn to control activity in the region during these feedback sessions. A separate group of
patients will be given a control form of feedback that we do not believe can have clinical
benefits. Our primary hypothesis is that the neurofeedback training will reduce OCD symptoms
more than the control feedback.

Original study design recruiting controls who were matched to the experimental group was
changed to a randomized design prior to enrollment of the first participant.

Inclusion Criteria:

- Primary Diagnosis of Current OCD, based on Diagnostic and Statistical Manual (DSM-IV)
criteria, a Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) score >=16

- Principle OCD symptoms- Primary symptoms must be either Cleaning/Contamination or
Checking; other symptoms okay

- Unmedicated (or medications stable for 8 weeks).

- Research group must be able to identify a target region in the orbitofrontal cortex
that is related to symptoms

Exclusion Criteria:

- Active Psychosis; Pervasive Developmental Disorder ; epilepsy or other major
neurological disorder

- History of major head trauma or psychosurgery

- Active Substance Abuse within 6 months

- Seizure disorder or other significant neurological disorder

- Active Suicidality

- Pregnancy

- severe claustrophobia, ferromagnetic metal in the body, a pacemaker or defibrillator,
or any other condition that would make MRI scanning unsafe or inappropriate

- any psychotropic medication other than a selective serotonin reuptake inhibitor (SSRI)
antidepressant, anafranil, or a low-dose hypnotic or anxiolytic taken on an as-needed
basis

- active cognitive/behavioral therapy initiated within the last 3 months (continuation
of established maintenance therapy that has been going on for longer than 3 months
will not be grounds for exclusion)
We found this trial at
1
site
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: Michelle Hampson, PhD
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials